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It has been known for over 25 years that CD4 T cell responses are restricted to a finite
number of peptide epitopes within pathogens or protein vaccines.These selected peptide
epitopes are termed “immunodominant.” Other peptides within the antigen that can bind
to host MHC molecules and recruit CD4 T cells as single peptides are termed “cryptic”
because they fail to induce responses when expressed in complex proteins or when in
competition with other peptides during the immune response. In the last decade, our labo-
ratory has evaluated the mechanisms that underlie the preferential specificity of CD4T cells
and have discovered that both intracellular events within antigen presenting cells, particular
selective DM editing, and intercellular regulatory pathways, involving IFN-γ, indoleamine
2,3-dioxygenase, and regulatory T cells, play a role in selecting the final peptide speci-
ficity of CD4 T cells. In this review, we summarize our findings, discuss the implications
of this work on responses to pathogens and vaccines and speculate on the logic of these
regulatory events.
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CD4 T CELL IMMUNODOMINANCE TO FOREIGN ANTIGENS
AND PATHOGENS IS PEPTIDE INTRINSIC AND DETERMINED
BY THE KINETIC STABILITY OF PEPTIDE: CLASS II
COMPLEXES
There has been tremendous interest in understanding the“rules”of
peptide selection by MHC class II molecules and the resulting elic-
itation of CD4 T cells during the immune response to pathogens or
protein vaccines. Many early models supported the importance of
proteolytic processing (1, 2) and structural constraints of the pep-
tide within the protein (3, 4) as primary features that determined
a peptide’s ability to recruit CD4 T cells. Collectively, these studies
suggested that the efficiency of proteolytic release of the peptide
was a key determinant of its ultimate immunodominance. How-
ever, systematic studies by our laboratory, summarized in Figure 1,
on foreign proteins have revealed that the immunodominance of
a class II: peptide is due to its intrinsic features, characterized
by its spontaneous kinetic stability (5–8). Peptides that success-
fully recruit CD4 T cells from the endogenous polyclonal T cell
repertoire display very slow off-rates (t 1/2 > 75 h at pH 5.3). In
contrast, peptides that fail to recruit CD4 T cells dissociate very
rapidly from class II molecules (t 1/2 < 10 h). Immunodominance
can be manipulated by amino acid changes at sites that anchor
the peptide to MHC class II, while leaving T cell receptor (TcR)
contact residues within the peptide unperturbed. This latter point
is critical, in that with T cell precursor frequency held constant, the
kinetic stability of class II peptide complexes behaves as a “rheo-
stat,” up- and down-regulating a peptide’s ability to recruit CD4
T cells. Finally, the finding that a peptide can be moved into a
different protein structure, or in different sites on a given protein
and maintain its immunodominant or cryptic character (9) has
indicated that the property of immunodominance is independent
of protein context. This conclusion has important implications
for vaccine strategies that seek to incorporate peptides into multi-
epitope vaccines [reviewed in Ref. (10, 11)] and suggests that such
approaches will allow a peptide to successfully recruit CD4 T cells
independently of the context into which it is incorporated and its
neighboring peptides.
THE ROLE OF DM EDITING IN SELECTING
IMMUNODOMINANT EPITOPES IN RESPONSE TO PROTEIN
VACCINATION
The MHC-linked DM protein was first discovered because of
its role in endosomal release of an invariant chain (Ii) degra-
dation product, a small peptide termed CLIP (Class II invariant
chain-derived peptide), that occupies the class II binding pocket
immediately after the synthesis of class II and Ii glycoproteins in
the endoplasmic reticulum (12). For many allelic forms of class
II, this release of CLIP is a requisite event in intracellular pep-
tide loading (13–18). We and others (19–24) showed that DM also
has an editing function for removal of endogenous self-peptides
from the class II binding pocket, thus shaping the repertoire of
“self” recognized by the immune system. Our laboratory showed
that for foreign exogenous antigens, DM editing within APC plays
a key role in determining immunodominance (5, 7, 19). Highly
stable peptide: class II complexes are resistant to DM editing and
emerge at the cell surface of APC with high density, while those
peptides that bound to MHC class II molecules with low stability
are removed by DM during endosomal processing (5–7, 9). These
latter types of peptides, cryptic epitopes, thus fail to reach the cell
surface at sufficient density to recruit CD4 T cells. The conclu-
sion regarding selective DM editing by our laboratory from in vivo
and in vitro studies and by others [reviewed in Ref. (7, 25–30)] is
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FIGURE 1 |The kinetic stability of peptide-MHC class II complexes is a
key biochemical parameter that dictates CD4T cell immunodominance.
Test peptide sequences with a range of kinetic stabilities were engrafted into
the MalE protein of E. coli and used to immunize mice. At the peak of the
immune response, CD4 T cells specific for the test peptide or the
endogenous MalE epitopes were quantified with IL-2 peptide-specific EliSpot
assays. The percent of the total antigen-specific CD4 T cells specific for the
test peptides are compared to the spontaneous dissociation rate of
peptide-MHC class II complexes at pH 5.3. (A)To visualize breakpoints in
immunodominance (e.g., cryptic, subdominant, dominant) the magnitude of
the peptide-specific response of different peptides are presented in order the
increasing kinetic stability of the I-Ad peptide complex. (B) A near linear
relationship is found when between kinetic stability and CD4 T cell
immunodominance when values in (A) are represented on a linear scale.
Filled symbols R2 =0.91, with all symbols R2 = 0.75. Data shown are adapted
from previous published studies (5, 8, 9, 36).
supported by biochemical and structural studies (31–35, 38) that
show that interactions that anchor peptides to class II molecules,
particularly at the peptides’s amino terminus, can render these
high stability peptide: class II complexes relatively resistant to DM
binding and editing.
BREAKPOINTS AND CEILINGS OF IMMUNODOMINANCE
The direct relationship observed between the kinetic stability of
peptide: MHC class II complexes has raised the question of the
threshold or breakpoint of immunodominance. If kinetic stability
of peptide: class II complexes plays a deterministic role in elici-
tation of CD4 T cell responses, one can ask, “what is the kinetic
stability breakpoint at which it can be certain that a peptide will
successfully elicit an immune response?” We have examined this
issue most extensively for the murine I-Ad molecule in response
to intact foreign antigens. Figure 1 indicates the peptide’s off-
rate from I-Ad at endosomal pH and relative immunodominance
when incorporated into the heterologous protein, MalE, the mal-
tose binding protein of E. coli (9, 37). This comparison allows
internal control for competing peptides within the antigen. From
these data (Figure 1A), one can conclude that the breakpoint that
allows a cryptic peptide to elicit a readily measurable fraction of
the response (e.g., at least 10% of the total response) will have
an off-rate (t 1/2) with I-Ad in the range of 60–80 h. We have not
observed any epitope that fails to recruit CD4 T cells that has
a half-life with I-Ad >70 h. Similarly, we have not observed any
peptide that successfully recruits CD4 T cells that has dissociation
half time from I-Ad that is <10 h.
In predictions of immunodominance, one issue that is unre-
solved is what features of the epitope dictates the maximal abun-
dance of CD4 T cells or “ceiling” of the response that any given
epitope can achieve. Our studies have revealed that although the
requirements for emergence of a peptide into immunodominance
are fairly predictable, some peptides show anomalies in the max-
imal number of CD4 T cells that they recruit, when frequencies
are measured at the peak of the response in the local draining
lymph node. This phenomenon of variable ceilings is illustrated
in Figure 1B, where different antigenic peptides are compared for
their ability to recruit CD4 T cells when in MalE. Although there
is a linear relationship and positive correlation (filled symbols
R2= 0.91), between kinetic stability of class II: peptide complexes
with immunodominance, some peptides (open symbols) deviate
from this relationship. The peptides with somewhat anomalous
behavior include Leishmania LACK [161–173] and MalE [69–84],
that recruit a larger fraction of the response than predicted from
their off-rates from I-Ad, and others, such as HA [126–138 T>M]
that recruit fewer than the expected number of CD4 T cells. We do
not yet understand what underlies these differences in maximal
response, but can imagine two distinct possibilities. The first is
that the DM sensitivity of a given peptide: MHC complex within
the priming APC deviates from its spontaneous off-rate, perhaps
as a function of the strength of the P1 pocket interaction or the
conformation of the complex around this region. For highly DM-
resistant peptides, the true initial epitope density displayed by the
priming dendritic cells (DC) may thus be increased relative to
others with similar spontaneous off-rates from class II. Others
may be particularly DM-sensitive and have lower initial epitope
density than predicted by their dissociation rate. In agreement
with this possibility are the findings of Stern and colleagues (30)
who found that DM susceptibility of class II complexes corre-
lates strongly with CD4 T cell recognition and the findings of
Mellins and coworkers whose studies revealed disparities between
susceptibility to DM editing and the intrinsic off-rates of class II:
peptide complexes (38). The second possibility to explain vari-
able ceilings relative to off-rates is that different peptides have TcR
contact residues that recruit variable numbers of T cell precursors
from the naïve repertoire. The techniques for measuring naïve
CD4 T cell precursors specific for single peptide: MHC class II
molecules using tetramer-based technology allowed an estimation
of number of T cells that recognize individual complexes. These
types of empirical approaches (39–41), as well as other theoretical
approaches (42) suggest that there can be a significant range in
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the number of T cells that can respond to different peptide: class
II complexes. Such variability has generally been ascribed to neg-
ative selection during intrathymic development. It is possible that
the final magnitude or ceiling of the response to peptides in the
local draining lymph nodes under competitive conditions may be
influenced by the precursor frequency of the peptide-reactive CD4
T cells in the host as well as DM editing.
It is important to note that the paradigm we have established
between the kinetic stability of peptide: class II complexes, DM
editing, and immunogenicity of peptides is expected to hold only
for pathogen-derived or foreign peptides that have little homology
to “self” proteins in the host. Deletion of CD4 T cells through par-
tial or total homology to self can dramatically re-shape the TcR
repertoire, eliminating many of the potentially antigen-reactive
CD4 T cells (43–46). There may also be enhanced TcR repertoire
selection for some related peptides due to positive selection with
peptide analogs (47). Thus, major perturbations of the T cell reper-
toire for epitopes closely related to “self” is likely to modulate the
magnitude of the elicited response and could change classification
of some peptides within the categories of immunodominant, sub-
dominant, or cryptic epitopes. Deducing the relative role of DM
editing in APC versus precursor frequency in a complex immune
response requires more explicit experimentation.
COMPETITIVE CD4 T CELL RESPONSES TO PEPTIDE
VACCINATION
Most of the mechanisms demonstrated or proposed to control
immunodominance have centered on the role that endosomal pro-
cessing and peptide loading onto class II plays in selecting the final
specificity of CD4 T cells. It was thus quite surprising to discover
in peptide vaccination studies that although cryptic peptides elicit
robust immune responses in vivo when introduced alone, when
they are co-introduced with other peptides, immunodominance
hierarchies are established (48). Interestingly, and similar to what
we had found for peptides within intact antigens, the immuno-
genicity of peptides during multi-peptide vaccination correlated
with their stability with the presenting class II molecule. Low sta-
bility cryptic peptides fail to recruit cells when co-introduced
with other, more dominant peptides, while high stability domi-
nant peptides successfully recruit CD4 T cells independently of
other peptides that are co-introduced into the host.
There are a number of key features we have discovered in this
control CD4 T cell specificity after multi-peptide immunization
(48, 49). First, the loss in responses requires that the competing
peptides be introduced in the same site, within the same emulsion
and most importantly, be presented on the same APC. Thus, the
inhibition is local rather than systemic. Second, bystander dom-
inant peptides do not inhibit the response to cryptic peptides
through competition for host MHC molecules. Although intu-
itively appealing, two pieces of data argue this possibility. First,
excess exogenously added irrelevant peptides that can bind to host
MHC class II molecules do not alter the ability of the agonist
cryptic peptide to elicit CD4 T cell responses. Second, dominant
peptides presented by unrelated host class II molecules are able
to down-regulate responses to co-introduced cryptic low stability
peptides (48). Another key aspect of the inhibition is that the ter-
mination of expansion occurs midway through the response (at
day 4–5). Until this point, there is no detectable influence of the
bystander peptides on the response. Finally, there is no evidence
that the CD4 T cells specific for dominant peptides render the APC
less able to recruit CD4 T cells by “trogocytosing” [reviewed in Ref.
(50, 51)] key co-stimulatory or adhesion molecules. Rather, all of
the data accumulated thus far suggest that ongoing responses to
unrelated dominant peptides down-modulate expansion of CD4
T cells to subdominant peptides through a network of locally
active regulatory elements that involve at least IFN-γ, indoleamine
2,3-dioxygenase (IDO), and regulatory T cells (Tregs).
The components involved in the mechanisms identified are
illustrated in Figure 2. All of the data accumulated to date sug-
gested that aborted expansion of CD4 T cells specific for cryptic
peptides by responses to high stability dominant peptides is caused
by alterations in the local environment during early CD4 T cell
expansion and differentiation. Because the expanding populations
of CD4 T cells specific for dominant peptides produce IFN-γ as
their primary effector cytokine, we tested both IFN-γ-deficient
mice and IFN-γR deficient mice and DC, respectively. Use of either
genetic model led to significantly diminished negative effects of
bystander dominant, CD4 T cell responses (49). IFN-γ is known
to have multiple avenues for suppressing CD4 T cell responses
[reviewed in Ref. (52–54)]. It can directly induce proliferative
arrest and apoptosis cells that bear the IFN-γ-R2 signaling com-
ponent of the IFN-γ receptor, which is selectively expressed on
Th2 cells and naïve CD4 T cells. IFN-γ can also act indirectly to
down-modulate adaptive T cell immunity through effects on DC,
promoting localized production of IDO. IDO is an immunomod-
ulatory enzyme that has multiple effects on immune responses
[reviewed in Ref. (52, 55–60)]. It catalyzes the rate-limiting step in
tryptophan degradation, inducing tryptophan deprivation, which
can induce the integrated stress response program in T cells (61).
Tryptophan degradation also leads to production of tryptophan
metabolites, such as kynurenines, that are broadly immunosup-
pressive. IDO-induced pathways also promote Treg through mod-
ification of DC. Several mechanisms have been proposed for the
generation of FoxP3-expressing Tregs through IDO. The trypto-
phan metabolite 3-HAA induces the expression of TGF-β in DC
and concurrently causes the conversion of T cells into Tregs (62).
Also, Treg generation can be facilitated by binding of kynurenine
to the aryl hydrocarbon receptor in T cells (63). These regulatory
pathways are critical in counter regulatory immunity to pathogens
and in self-tolerance pathways [reviewed in Ref. (55, 64–66)]. We
found that inhibition of production of IDO, use of genetic mod-
els to eliminate production of, or responsiveness to IFN-γ and
finally depletion of Treg, each help rescue suppressed responses
to cryptic peptides during multi-peptide immunization. Together,
our data suggest that IFN-γ, IDO, and Treg all participate in shap-
ing the specificity of the CD4 T cells elicited during multi-peptide
immunization. These regulatory events and mediators also likely
participate in the normal contraction of immune responses.
SUMMARY AND PERSPECTIVES
Our studies have revealed two distinct mechanisms by which the
immune system selects for CD4 T cell reactivity to peptides that
persist on the MHC class II molecule, illustrated in Figure 2.
Selective DM editing within DC promotes an initial high epitope
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FIGURE 2 | CD4T cell immunodominance is shaped by two distinct and
selective stages during priming. In the first stage of selection of CD4 T
cells, intracellular DM “editing” promotes immunodominance of high stability
class II: peptide complexes by dictating the initial epitope density on priming
DC, which allows differential initial recruitment of CD4 T cells. In the second
stage, or after multi-peptide immunization, regulatory events induced by
dominant CD4 T cells (indicated in blue), including production of IFN-γ, and
resulting IDO and Treg induction and production of kynurenines further refine
the CD4 repertoire by inhibiting full expansion of CD4 T cells specific for lower
stability complexes, indicated in yellow and green.
density of these peptides with class II molecules on the priming
APC, while simultaneously removing peptides that cannot sustain
interactions with class II. Further regulatory events during com-
petitive responses provide a selective advantage to peptides that
persist with class II molecules. The conclusion from this body of
work, that there are complementary, reinforcing mechanisms to
focus CD4 T cells on peptides which can bind very stably to class
II molecules, suggests that persistence per se of peptide: class II
complexes provide distinct advantages in the adaptive immune
response.
There is accumulating evidence that CD4 and CD8 T cells
differ in regard to their reliance on continued engagement of
their TcR during an immune response. Unlike CD8 T cells that
may need only a single encounter with APC to initiate expan-
sion and differentiation (67), CD4 T cells or their progeny appear
to require multiple contacts with antigen-bearing APC in vivo
to expand and differentiate (68). For the delivery of CD4 T cell
help to B cells, peptides that can persist on B cells may more
effectively recruit follicular helper cells. Even beyond the acute
phase of the immune response, CD4 T cells may rely on repeated
TcR engagement for some functions (69, 70). Early work on the
need for persistent antigen on immunological memory suggested
that maintenance of memory CD8 T cells was independent of
continued antigen and instead relied heavily on homeostatic pro-
liferation induced by cytokines such as IL-15 [reviewed in Ref.
(71)]. CD4 T cells seem to be less well sustained by cytokines
alone [reviewed in Ref. (72)] and recent data suggest that low lev-
els of peptide: class II complexes may be critical for maintenance
of CD4 T cell memory (73). CD4 T cell dependence on periodic
TcR engagement for expansion, differentiation, and memory may
underlie the focus of the CD4 T cell response on peptides that
bind very stably to the class II molecule. At least during the ini-
tial phase of the immune response, even if antigen is eliminated
quickly, there will be sufficient complexes on APC to initiate CD4
T cell recognition and then sustain expansion and differentiation.
Selective peptide presentation via DM editing, even in the face
of diminishing antigen, will promote selective priming of CD4
T cells specific for these complexes, “pruning” the population of
CD4 T cells specific for lower affinity ligands. Such early shap-
ing of the CD4 T cell repertoire may allow the early expanding
polyclonal responses to be populated by the most desirable of
CD4 T cells, thus preventing proliferation of CD4 T cells that
later may not be of the most utility in establishing memory or
provision of T cell help for B cells. The finding that high sta-
bility class II: peptide complexes also favor a diverse CD4 TcR
repertoire (74) suggests an additional advantage for these types of
complexes in endowing the host with protective immunity. Com-
bined with this early repertoire selection is a second selection event
that occurs after peptides are expressed at the APC surface. Here,
regulatory events further select CD4 T cells specific for complexes
that persist on class II molecules through active suppression of
CD4 T cells specific for less “fit” peptide: MHC complexes. These
sequential, independent mechanisms likely account for the clear
preference of CD4 T cells for high affinity stable peptide: class II
complexes.
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